VA awards $4.55M for Lenalidomide to Exelan Pharmaceuticals, ensuring patient care through full and open competition
Contract Overview
Contract Amount: $4,548,792 ($4.5M)
Contractor: Exelan Pharmaceuticals Inc
Awarding Agency: Department of Veterans Affairs
Start Date: 2026-01-15
End Date: 2027-01-14
Contract Duration: 364 days
Daily Burn Rate: $12.5K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 2
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: LENALIDOMIDE FOR THE DURHAM VAMC FOR PATIENT CARE
Place of Performance
Location: BOCA RATON, PALM BEACH County, FLORIDA, 33432
State: Florida Government Spending
Plain-Language Summary
Department of Veterans Affairs obligated $4.5 million to EXELAN PHARMACEUTICALS INC for work described as: LENALIDOMIDE FOR THE DURHAM VAMC FOR PATIENT CARE Key points: 1. The contract focuses on essential pharmaceutical preparation manufacturing for patient care. 2. Exelan Pharmaceuticals Inc. is the sole awardee, indicating a specific market position. 3. The award utilizes a firm fixed price contract, providing cost certainty. 4. This procurement supports the Durham VA Medical Center's operational needs.
Value Assessment
Rating: good
The award of $4.55M for Lenalidomide appears reasonable given the specialized nature of pharmaceutical preparations. Benchmarking against similar VA or DoD contracts for this drug would provide a more precise assessment of value.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting a robust price discovery process. This method typically leads to more competitive pricing by allowing all eligible vendors to bid.
Taxpayer Impact: The competitive award process aims to ensure taxpayer funds are used efficiently for necessary medical supplies.
Public Impact
Ensures continued access to critical medication for veterans. Supports the operational readiness of the Durham VA Medical Center. Promotes fair market competition within the pharmaceutical supply chain.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price fluctuations if market conditions change significantly.
- Dependence on a single supplier for this critical medication.
Positive Signals
- Awarded through full and open competition.
- Firm fixed price contract provides budget predictability.
- Supports patient care at a VA facility.
Sector Analysis
The pharmaceutical preparation manufacturing sector is highly regulated and critical for healthcare. Spending in this area is driven by patient needs and the availability of specialized drugs like Lenalidomide.
Small Business Impact
While this specific award went to Exelan Pharmaceuticals Inc., the 'full and open competition' nature of the award theoretically allows for small business participation if they meet the qualifications and bid successfully.
Oversight & Accountability
The Department of Veterans Affairs is responsible for overseeing this contract to ensure timely delivery and quality of the pharmaceutical product, safeguarding patient well-being and taxpayer investment.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Sole awardee concentration risk
- Potential for price escalation in future contract periods
- Dependence on specific manufacturing capabilities
- Supply chain vulnerability for critical pharmaceuticals
Tags
pharmaceutical-preparation-manufacturing, department-of-veterans-affairs, fl, delivery-order, 1m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $4.5 million to EXELAN PHARMACEUTICALS INC. LENALIDOMIDE FOR THE DURHAM VAMC FOR PATIENT CARE
Who is the contractor on this award?
The obligated recipient is EXELAN PHARMACEUTICALS INC.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $4.5 million.
What is the period of performance?
Start: 2026-01-15. End: 2027-01-14.
What is the historical pricing trend for Lenalidomide from this vendor or similar vendors?
Analyzing historical pricing data for Lenalidomide from Exelan Pharmaceuticals Inc. or comparable suppliers is crucial. This trend analysis would reveal if the current $4.55M award represents a fair market price or if there have been significant escalations or reductions over time, impacting the overall value for the VA.
What are the risks associated with relying on a single supplier for this critical medication?
Reliance on a single supplier, even one secured through competitive bidding, introduces risks such as supply chain disruptions due to unforeseen events (e.g., manufacturing issues, natural disasters, geopolitical instability). This could lead to medication shortages, impacting veteran patient care and potentially requiring emergency procurement at higher costs.
How effectively does this contract ensure the consistent availability of Lenalidomide for patient care?
The contract's duration of one year with a potential for renewal, coupled with a firm fixed price, suggests a structured approach to ensuring consistent availability. However, effectiveness hinges on Exelan's manufacturing capacity, supply chain resilience, and adherence to delivery schedules, all of which require ongoing VA oversight.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Offers Received: 2
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 370 W CAMINO GARDENS BLVD STE 204, BOCA RATON, FL, 33432
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Not Designated a Small Business, Special Designations
Financial Breakdown
Contract Ceiling: $4,548,792
Exercised Options: $4,548,792
Current Obligation: $4,548,792
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Parent Contract
Parent Award PIID: 36F79720D0227
IDV Type: FSS
Timeline
Start Date: 2026-01-15
Current End Date: 2027-01-14
Potential End Date: 2027-01-14 00:00:00
Last Modified: 2026-01-14
More Contracts from Exelan Pharmaceuticals Inc
- Oseltamivir Phosphate 75MG Capsules (NDC: 76282-0704-45); 10 CT. Blisters Packs and Oseltamivir Phosphate 30MG Capsules (NDC: 76282-0702-45); 10 CT. Blisters Packs — $74.1M (Department of Health and Human Services)
- Lenalidomide for the Salisbury Vamc, Charlotte HCC, and Kernersville HCC — $5.1M (Department of Veterans Affairs)
- Lenalidomide for the Richmond Vamc for Patient Care — $4.1M (Department of Veterans Affairs)
- VA Long Beach Lenalidomide DO — $3.7M (Department of Veterans Affairs)
- Lenalidomide for Fayetteville Vamc Patient Care — $3.5M (Department of Veterans Affairs)
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)